PTO/SB/08A/B (09-08)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

Complete If Known			
Application Number	10/518,279		
Filing:Date	December 15, 2004		
First Named Inventor	Phillip Martin Cowley		
Art Unit	1624		
Examiner Name	Emily B. Bemhardt		
Attorney Docket Number	2002.735US		

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
				1	

1

		FOREI	GN PATENT	DOCUMENTS		
Examiner Cite No.1	Cito	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
					Passages or Relevant Figures Appear	T
ZEB	1.	EP1243268	09-25-2002	Nippon Shinyaku Co.		
-1	2.	WO 98 06715	02-19-1998	SmithKlineBeecham Corp.		
EB	3.	WO 01 43746	06-21-2001	Nippon Shinyaku Co.		V

EXAMINER: Initial if reference considered, whether or not citation is no conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	۲۶.
JB	4. 🗸	Battaglia et. al., "Indole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H ₁ -receptor antagonists," Eur. J. Med. Chem. 34'.1999) 93-105.	
	5. 🗸	Dinsmore et. al., "Recent Advances in the Synthesis of Diketopiperazines," Tetrahedron 58 (2002) 3297-3312.	
	6. 🗸	Duflos et. al., "N-Pyridinyl-Indole-3-(alkyl)carboxamides and derivatives as potential systemic and topical inflammation inhibitors," Eur. J. Med. Chem. 36 (2001) 545-553.	
	7. J	Howlett et. al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol.," <i>Pharmacol Rev</i> 54 (2002) 161–202.	
	8.	Iversen et al. "Cannabinoids: a real prospect for pain relief?" Current Opinion in Pharmacology 2 (2002) 50-55.	
		Jacobsen-etal., "Piperazine-Imidazo[1,5-a]quinoxaline Ureas-as-High-Alfinity GABA _x Ligands- of Dual Functionality," <i>J. Med. Chem. 42</i> (1999) 1123-1144.	
	10. 🖊	Jung et. al., "Organic Chemistry of L-Tyrosine. 1. General Synthesis of Chiral Piperazines from Amino Acids," J. Org. Chem. 50 (1985) 4909-4913.	
	11.	Peterson et. al., "Decarbonylation of 3-Indoleglyoxalyl Chloride," J. Org. Chem. 23 (1958) 303-304.	
	12. 🗸	Stratowa et al., "Use of a Luciferase Reporter System for Characterizing G-Protein-Linked Receptors," Curr. Opin. Biotech. 6 (1995) 574-581.	
	13. /	Swain et. al., "Novel 5-HT ₃ Antagonists. Indole Oxadiazoles," <i>J. Med. Chem. 34</i> (1991) 140-	
V	14. 🗸	Török et. al., "General Synthesis of Methyl- and Dimethyl-cyclobutanes from Simple 1.3-Diols by Phase Transfer Catalysis," <i>J. Chem. Soc. Perkin Trans. 1</i> (1993) 801-804.	

*EXAMINER: thittal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant is to place a check mark here if English language Translation is attached.

			*********	4	
Examiner	5 Boundary H	Date	7	120	7-5
Signature	X Demhaudt	Considered		100	101